Table 1.
Drugs affected by mutations detected in six of the thirty-seven recently HIV positive individuals in RT-region of pol gene.
| High Risk group/State | AGE& gender | NRTI | NNRTI | Drugs Affected |
|---|---|---|---|---|
| MSM Haryana | 26/Male | L74V | Intermediate Resistance: Abacavir ( ABC) | |
|
| ||||
| IDU Chandigarh | 44/Male | K219N | Potential Low Level Resistance: Zidovudine (AZT) | |
|
| ||||
| FSW Chandigarh | 25/Female | K219R | Potential Low Level Resistance: Zidovudine (AZT) | |
|
| ||||
| FSW Chandiagrh | 38/Female | K219R | Potential Low Level Resistance: Zidovudine (AZT) | |
|
| ||||
| IDU Chandigarh | 21/Male | Y181C | High-Level resistance: Nevirapine (NVP) | |
| Intermediate Resistance: efavirenz (EFV), etravirine (ETR), rilpivirine (RPV) | ||||
|
| ||||
| IDU Chandigarh | 32/Male | Y181C | High-Level resistance: Nevirapine (NVP) | |
| Intermediate Resistance: efavirenz (EFV), etravirine (ETR), rilpivirine (RPV) | ||||